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Objectives: This study assesses whether pegylated interferon and ribavirin is
cost-effective compared with no antiviral treatment provided in routine clinical practice,
for different patient subgroups.
Methods: The cost-effectiveness analysis (CEA) uses a Markov decision model to
estimate the lifetime cost per quality-adjusted life-year (QALY) of antiviral treatment
compared with no treatment. The model is populated with data on sustained virological
responses, costs, and transition probabilities all taken from a large representative sample
of UK cases and centers (Trent HCV database).
Results: The CEA found that pegylated interferon and ribavirin was cost-effective for
most patient subgroups. The CEA found that for patients with genotype non-1, the
intervention led to cost reductions and gains of at least 0.5 QALYs. For genotype 1 cases
with mild or moderate disease, and younger cirrhotic patients (aged 40 or less), costs per
QALY remained below £20,000 ($40,000 or €29,000). For genotype 1 cases with cirrhosis
aged 50, the mean cost per QALY rose to over £60,000 ($120,000 or €87,000).
Conclusions: The study concludes that, based on cost and effectiveness data collected
from routine clinical practice, treatment with pegylated interferon and ribavirin is generally
cost-effective. The study shows that there are variations according to patient subgroup
and for older (aged 50 or over) genotype 1 patients with cirrhosis, antiviral treatment
appears less cost-effective.
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Antiviral therapy
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It has been estimated that over 170 million people worldwide
have been infected with the hepatitis C virus (HCV) (1), and
HCV infection is the most common cause of liver trans-
plantation (24;26). The burden of the disease is large and is
predicted to increase over the next decade (15;29;34). Multi-
national randomized controlled trials (RCTs) have found that
a combination of pegylated interferon and ribavirin is effec-
tive in achieving a sustained virological response (SVR) for
at least 40 percent of cases with genotype 1 and 75 percent of
cases with genotype non-1 (7;12;14;738). Subsequent cost-
effectiveness studies have used these SVRs in economic mod-
els, and concluded that combination therapy is cost-effective
for patients with chronic hepatitis C (27;28). Based partly
on evidence from these studies, National Institute for Health
and Clinical Excellence (NICE) recommended that combina-
tion therapy should be provided for all patients with chronic
hepatitis C (21).
However, cost-effectiveness estimates based on multina-
tional RCTs may not reflect the costs and cost-effectiveness
of providing antiviral therapy in routine clinical practice.
Policy makers such as NICE also require cost-effectiveness
studies that provide realistic estimates of the value of deliv-
ering interventions in “real-world” settings. A further issue
is that, although antiviral therapy is recommended for all
patients with chronic hepatitis C, it may be that there are par-
ticular subgroups for whom antiviral treatment is not cost-
effective. Whereas previous cost-effectiveness studies have
shown that antiviral therapy is more cost-effective for pa-
tients with genotype non-1, further subgroup analyses have
been limited (13;35).
This study aims to examine the cost-effectiveness of
providing pegylated interferon and ribavirin for different pa-
tient subgroups based on costs and outcomes observed in
routine clinical practice. The study uses data from the Trent
HCV cohort study, a large observational study that includes
a range of subgroups of patients with chronic hepatitis C
(25). A key advantage of this data set is that it only com-
prises patients who attend nontertiary referral centers and is
representative of the care provided in a large UK regional
population. Using data from this study may therefore pro-
vide realistic estimates of the cost-effectiveness of providing
the antiviral treatment in routine practice for different patient
subgroups.
METHODS
Overview
This study evaluated the cost-effectiveness of antiviral treat-
ment with pegylated interferon and ribavirin compared with
no treatment for different patient subgroups. The treatment
group considered for inclusion all treatment naive patients
in the Trent HCV Cohort who have been treated with com-
bination therapy with pegylated interferon and ribavirin. In-
dividuals with HIV co-infection, hemophilia, or end-stage
renal disease were excluded. To allow outcome to be as-
sessed, only those patients who completed treatment in time
to have a 6 months post-treatment PCR taken before the end
of April 2006 were entered into the current analysis. No fur-
ther selection criteria were applied and 347 cases met the
inclusion criteria. Of these patients 33 percent had geno-
type 1 and 59 percent had intravenous drug use as their
main risk factor for HCV, but very few patients (n = 3)
were current injectors. Further details of the patient sample
are given in Supplementary Table 1 (which can be viewed
online at www.journals.cambridge.org/thc) and in Thomson
et al. (33). A total of 32 cases were excluded (25 without
liver biopsy data, and 7 cases with missing data on the
dosage of pegylated interferon), leaving 315 patients for
analysis.
The treatment regimen aimed to follow NICE guide-
lines (20;21): patients were treated with either pegylated
interferon-α2a 180 mg weekly (Pegasys; Roche) or pegy-
lated interferon- α2b 1.5 mg/kg (Viraferon; Schering Plough)
and ribavirin (Copegus; Roche or Rebetol, given per weight
according to license). Local protocols allowed some devia-
tion from this general guidance, for example in encouraging
patients with cirrhosis to have antiviral therapy for 52 weeks.
The no-treatment groups were assumed to have visits and in-
vestigations associated with routine monitoring as reported
in a recent NHS health technology assessment (37).
The subgroups of interest for the cost-effectiveness anal-
ysis were specified in advance. The choice of groups was
guided by evidence identifying the key factors associated
with SVR and disease progression. HCV genotype, baseline
viral load, presence of bridging fibrosis/cirrhosis, and age
are independent predictors of treatment outcome (12;14;17),
while sex, age at infection, age at biopsy, and alcohol use are
associated with the rate of fibrosis progression (23;30;31;36).
In the Trent data set, information was available to examine
the cost-effectiveness of antiviral therapy by the following
patient subgroups: HCV genotype (1 versus non-1), baseline
fibrosis stage (defined based on the Ishak scale for fibrosis
where 0–2 is categorized as mild disease, 3–5 as moderate
disease and 6 as cirrhosis), age at presentation for treatment
(30 versus 40 versus 50 years old), and sex.
A Markov decision model simulated the lifetime costs
and outcomes associated with antiviral treatment compared
with no treatment for each patient subgroup. This cohort
model makes the same methodological assumptions as a pre-
viously described cost-effectiveness model (13). The model’s
structure was extended to allow for comprehensive sub-
group analyses and to incorporate new data from the Trent
HCV cohort study on the effectiveness and costs of an-
tiviral therapy. For each subgroup of patients the model
followed the two hypothetical cohorts through a series of
health states until death from liver disease or other causes
(Supplementary Figure 1, which can be viewed online at
www.journals.cambridge.org/thc). In each annual cycle, pa-
tients faced a probability of staying in the same health state,
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Table 1. Input Parameters, Mean (SE)
Age at treatment
: 30 Years 40 Years 50 Years
Probabilities of SVR Mild HCV
Genotype 1 0.72(0.08) 0.57(0.07) 0.40(0.09)
Genotype non 1 0.84(0.04) 0.82(0.04) 0.80(0.05)
Moderate HCV
Genotype 1 0.53(0.13) 0.36(0.09) 0.23(0.07)
Genotype non-1 0.73(0.08) 0.70(0.06) 0.67(0.06)
Cirrhosis
Genotype 1 0.20(0.18) 0.11(0.11) 0.06(0.06)
Genotype non-1 0.44(0.12) 0.40(0.1) 0.37(0.09)
Transition Probabilities
Mild-Moderate
Genotype 1 0.015(0.003) 0.023(0.004) 0.035(0.007)
Genotype non-1 0.022(0.004) 0.033(0.005) 0.049(0.008)
Moderate-Cirrhosis
Genotype 1 0.021(0.006) 0.032(0.008) 0.048(0.013)
Genotype non-1 0.03(0.007) 0.046(0.011) 0.069(0.016)
HRQOL (EQ-5D, absolute changes)
Mild stage 0.77(0.02)
During treatment for mild HCV 0.66(0.04)
SVR following treatment for mild HCV 0.82(0.04)
Moderate stage 0.66(0.03)
During treatment for moderate HCV 0.55(0.04)
SVR following treatment for moderate HCV 0.71(0.05)
Cirrhosis 0.55(0.05)
During treatment for patients with cirrhosis 0.44(0.04)
SVR following treatment for cirrhosis 0.60(0.04)
Decompensated cirrhosis, HCC 0.45(0.03)
Annual costs
Mild HCV, no-treatment group £162 (£27)
Moderate HCV, no-treatment group £860 (£64)
Cirrhosis, no-treatment group £1,341 (£231)
Decompensated cirrhosis £10,746 (£1,519)
SVR, sustained virological response; HCV, hepatitis C virus; HCC, hepatocellular carcinoma; HRQOL, health-related quality
of life.
moving to the subsequent one, or dying. Each treatment co-
hort was assigned a probability of having a SVR. Patients that
reached the SVR state no longer progressed. The life-years
accumulated in each health state were multiplied by the costs
and health-related quality of life (HRQOL) associated with
that state. The model estimated the average quality-adjusted
life-years (QALYs) and costs over the lifetime for the treat-
ment and no-treatment cohorts, for each of the subgroups
described.
Effectiveness and Natural History Data
The data on the SVRs after antiviral therapy for different
patient groups were obtained from the Trent HCV database.
The Trent HCV cohort based study assessing the effective-
ness of pegylated interferon and ribavirin has been reported
in detail elsewhere (33). Data from a sample of 315 patients
were available for the analysis. Multivariate logistic regres-
sion analysis was used to estimate the independent effect on
SVR of the following variables: sex, viral genotype (1 versus
non-1), and disease stage (mild, moderate, cirrhosis) at the
beginning of treatment. The coefficients obtained from the re-
gression analysis were then used to predict the probability of
a SVR for each subgroup of interest in the cost-effectiveness
analysis (see Appendix 1). The predicted probabilities of
a SVR ranged widely across the subgroups (Table 1), from
0.06 for 50-year-old patients with cirrhosis and genotype 1 to
0.84 for 30-year-old patients with mild disease and genotype
non-1.
The probabilities of progressing from mild disease to
cirrhosis were estimated by analyzing longitudinal data from
the Trent database as performed in Sweeting et al. (30). The
Trent database was chosen because there is no tertiary refer-
ral liver center within the region, and therefore the estimates
of disease progression will be representative of progression
rates of patients presenting for treatment in the UK more
generally (12). The models estimated the transition proba-
bilities between these early stages, adjusted for age at in-
fection, biological age, alcohol use, genotype, and sex, for
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Table 2. Costs of Antiviral Treatment, Mean (SE)
Costs of Outpatient Visits, £
N
Treatment
Duration, weeks Drug Costs, £
Pretreatment
Assessment Treatment
Mild HCV
Genotype non-1 105 25.1 (0.76) £6,475 (£202.6) £760 (£31.6) £644 (£36.6)
Genotype 1 53 36.4 (2.17) £9,567 (£635.0) £798 (£33.1) £621 (£44.4)
Moderate HCV
Genotype non-1 70 25.0 (1.16) £6,321 (£320.5) £843 (£30.2) £569 (£55.4)
Genotype 1 43 36.2 (2.41) £9,383 (£668.0) £850 (£31.4) £653 (£89.0)
Cirrhosis
Genotype non-1 31 29.1 (2.44) £7,131 (£601.4) £836 (£33.9) £929 (£81.0)
Genotype 1 13 29.7 (4.73) £7,825 (£1,296.5) £773 (£44.2) £1,274 (£270.2)
HCV, hepatitis C virus.
each subgroup of interest in the cost-effectiveness analysis.
The key transition probabilities in the model are presented
in Table 1. Transition probabilities to subsequent stages were
taken from the study by Fattovich et al. and from a UK mul-
ticenter liver transplantation study (10;37).
Costs and HRQOL
The cost measurement took a health service perspective and
measured inpatient and outpatient costs directly attributable
to HCV. To enable accurate assessment of the costs and out-
comes associated with antiviral treatment and “no treatment,”
the model used input parameters based on patient-level data
collected alongside routine clinical practice. The costs for
the “no treatment” cohort are reported in Table 2. For the
treatment cohort, data on the duration and dosage of antivi-
ral treatment were available for 315 patients from the Trent
HCV database. Complete data on the number of outpatient
visits, day cases, and patients’ admissions to inpatient depart-
ments during treatment and the first 6 months of follow-up
were obtained from five of the study hospitals (n = 227).
Details of outpatient visits (doctor and nurse-led) were col-
lected from patients’ case-notes and nurses’ diaries. Dates
and duration of patients’ inpatient admissions were retrieved
from hospital databases. The drug unit costs were taken from
the British National Formulary (5). All other unit costs were
taken from a previous study (13). Data on resource use and
unit costs were combined to give the costs of assessment for
treatment, antiviral treatment, monitoring costs, and follow-
up costs in the 6 months post-treatment for each subgroup.
All costs were adjusted to 2006–07 prices using appropriate
price indices (8). The main cost results were converted into
U.S. dollars and euros using 2007 annual average exchange
rates (£: $2.00 or €1.46) to assist with the interpretation of
the results (2).
HRQOL estimates for patients at each stage of the dis-
ease were taken from Grieve et al. and Longworth and Bryan.
(13;16). These studies recorded each patients’ HRQOL using
the Euroqol (EQ-5D) questionnaire, which records HRQOL
on a scale from 0 (dead) to 1 (perfect health) (Table 2).
Cost-Effectiveness Analysis
The model estimated the total costs per patient and total life-
time QALYs for the treatment and no-treatment cohorts. Fu-
ture costs and outcomes were discounted at the recommended
rate of 3.5 percent per annum (19). The results of the anal-
ysis were presented as incremental cost-effectiveness ratios
(ICER) expressed as cost per QALY, the difference between
treatment and no-treatment groups in mean lifetime costs di-
vided by the corresponding differences in QALY gains. This
was reported for each patient subgroup. Multivariate Monte
Carlo sensitivity analyses were undertaken to consider the
sampling uncertainty around the mean estimates. These sim-
ulations were undertaken by re-sampling 5,000 times from
the appropriate input distributions for each model parame-
ter (beta distributions for probabilities and HRQOL, gamma
distributions for costs). The results from these simulations
were used to report cost-effectiveness acceptability curves
(CEAC) (3;4). CEACs show the probability that an interven-
tion is cost-effective for different levels of willingness to pay
for the cost per QALY gained. For example, NICE has stipu-
lated that it regards interventions that have a cost per QALY of
less than £20,000 to £30,000 [$40,000 to $60,000 or €29,200
to €43,800] per QALY as relatively cost-effective. However,
NICE guidance for cost-effectiveness studies requires that
the analysts report the probability that the intervention is
cost-effective for a range of cost per QALY thresholds (e.g.,
from 0 to £100,000 per QALY).
Methodological Sensitivity Analysis and
Threshold Analysis
To investigate the robustness of the cost-effectiveness es-
timates to assumptions made in the base-case model, the
following sensitivity analyses were performed.
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• Changes in HRQOL following SVR. HRQOL estimates for
patients following an SVR were only available for patients with
mild disease. In the base-case analysis, it was assumed that pa-
tients with moderate disease or cirrhosis had the same absolute
gain in HRQOL as patients with mild disease. The sensitivity
analysis examined whether the results changed if instead it was
assumed that following a SVR, the relative gain in HRQOL was
the same across disease stages.
• Monitoring following SVR. The base-case analysis assumed
that patients with cirrhosis were followed-up for 5 years follow-
ing an SVR, whereas patients in the precirrhosis health states
were followed up for 2 years following a SVR. The sensitivity
analysis examined the impact of extending these follow-up pe-
riods to 5 years for the precirrhosis health states and to lifetime
monitoring for patients having a SVR following cirrhosis.
• Unit costs. The base-case analysis applied cost data for the “no
treatment” stages from the UK mild hepatitis C study, which
included centers with relatively high unit costs. To examine the
impact of lower unit costs, the unit costs for all disease stages
were reduced by 30 percent.
• Increased all-cause death rates for patients with cirrhosis.
The base-case analysis followed the approach taken in previous
cost-effectiveness models and assumed that the all-cause death
rates for patients with hepatitis C were the same as for the general
population. However, to test whether the results were robust to
patients with cirrhosis having a higher probability of all-cause
death, this rate was doubled in the sensitivity analysis (7).
• Reduced probability of Hepatocellular Carcinoma for non-
SVR. The base-case analysis assumed that those patients who
received antiviral treatment but did not have an SVR had the
same probability of progression from cirrhosis to hepatocellular
carcinoma (HCC) as the no-treatment cohort. Antiviral treatment
for patients with cirrhosis may be associated with a reduction in
the probability of progressing to HCC even in the absence of a
SVR (22). The sensitivity analysis tested the impact of reduc-
ing the probability of progression to HCC following antiviral
treatment for patients with cirrhosis.
RESULTS
The mean duration of antiviral treatment for all cases in-
cluded in the study was 36 weeks for patients with genotype
1 and 25 weeks for patients with genotype non-1 (Table 2).
For patients with mild or moderate disease and genotype
1, treatment duration was on average 11 weeks longer than
for patients with genotype non-1. For patients with cirrhosis,
treatment durations were similar across genotype groups. For
all patient groups, the mean costs of the intervention were
higher for patients with genotype 1 (Table 2). The costs of
assessing a patient for treatment were lower for patients with
mild disease as a lower proportion of these cases had a liver
biopsy before treatment. For example, for patients with mild
disease, 65 percent of patients had a liver biopsy in the 18
months before treatment, compared with 89 percent of cases
with moderate disease Following an SVR, the mean annual
Table 3. Cost-Effectiveness Results for Patients Aged 40 at
Presentation for Treatment
Treatment No Treatment Difference
Mild HCV
Genotype 1
Mean QALYs 15.78 14.67 1.11
Mean cost £16,104 £12,228 £3,876
cost per QALY £3,507
Genotype non-1
Mean QALYs 16.25 14.20 2.05
Mean cost £10,750 £15,362 −£4,611
cost per QALY AVT dominates
Moderate HCV
Genotype 1
Mean QALYs 12.59 11.64 0.95
Mean cost £29,122 £30,044 −£922
cost per QALY AVT dominates
Genotype non-1
Mean QALYs 13.43 11.15 2.29
Mean cost £17,250 £32,442 −£15,193
cost per QALY AVT dominates
Cirrhosis
Genotype 1
Mean QALYs 8.12 7.71 0.40
Mean cost £47,709 £44,476 £3,233
cost per QALY £8,017
Genotype non-1
Mean QALYs 9.45 7.71 1.74
Mean cost £34,977 £44,539 −£9,561
cost per QALY AVT dominates
HCV, hepatitis C virus; AVT, antiviral therapy; QALY, quality-adjusted
life-years;
costs for the first 2 years of follow-up for patients with mild
disease, moderate disease, and cirrhosis were £202, £247,
and £437, respectively.
The results for the cost-effectiveness analysis are pre-
sented for patients aged 40 in Table 3. For most patient
groups, the estimated lifetime costs for the antiviral treat-
ment group were less than for the no-treatment group: the
short-term costs of the intervention were more than offset
by the reductions in morbidity costs from preventing disease
progression. For example, for 40-year-old cases with mild
disease and genotype non-1, 82 percent of treated cases were
predicted to have a SVR. The overall mean lifetime costs
were therefore lower for the treatment (£10,750 [$21,500
or €15,695]) than for the no-treatment group, (£15,362
[$30,724 or €22,429]), and incremental costs were nega-
tive (−£4,611 [−$9,222 or €6,732]) (Table 3). The cost-
effectiveness analysis found that for patients aged 40 the in-
tervention was associated with gains in QALYs for all groups
(Table 3).
For all the groups of patients with genotype non-1, an-
tiviral treatment led to lower costs and gains in QALYs,
the incremental costs per QALY were negative, indicat-
ing that treatment was highly cost-effective. For other
patient groups where antiviral treatment was associated
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Figure 1. Cost-effectiveness acceptability curves (CEACs) showing the cost-effectiveness of antiviral therapy for genotype 1
patients with mild disease and cirrhosis 40 and 50 years of age.
with additional costs these were mainly small relative to
the QALYs gained, and the ICERs were below £20,000
(Supplementary Table 2, which can be viewed online at
www.journals.cambridge.org/thc).
The model estimated that the mean lifetime costs were
highest for cases presenting with cirrhosis. For older cirrhotic
patients (aged 50 and over) with genotype 1, only 6 percent
of treated cases had an SVR. This led to a very low esti-
mate for the QALYs gained (0.09) relative to the additional
costs associated with treatment (£5,539). The net effect was
that antiviral treatment for this group had a cost per QALY
of over £60,000 ($120,000 or €87,000) (Supplementary
Table 2).
The CEAC incorporated the sampling uncertainty sur-
rounding the model’s input parameters. The results showed
that at a threshold of £20,000 per QALY, the probability that
the intervention was cost-effective exceeded 0.5 for the ma-
jority of the patient groups. For example, for patients aged
40 with mild disease and genotype 1, the probability that the
intervention was cost-effective was 0.94 (Figure 1). The only
group for whom the intervention was not cost-effective at
this threshold was older cirrhotic patients (aged 50 and over)
with genotype 1, for these cases the probability that the in-
tervention was cost-effective at £20,000 per QALY was 0.31
(Figure 1).
The sensitivity analysis showed that the results were
robust to changes in four of the five main assumptions
for each of the subgroups considered even for those pa-
tients aged 40 and 50 with mild disease and cirrhosis
(Supplementary Table 3, which can be viewed online at
www.journals.cambridge.org/thc). Assuming that the rela-
tive rather than absolute gain in HRQOL was the same across
all disease stages reduced the costs per QALY for patients
with cirrhosis, but they remained above £50,000 ($100,000
or €73,000) for cases with genotype 1 aged 50 (Supplemen-
tary Table 3). Increasing the follow-up period after SVR,
and reducing unit costs made the intervention less cost-
effective, but did not change the conclusion that it was cost-
effective for all groups apart from older cirrhotic patients with
genotype 1.
The only parameter to which results proved sensitive
was the probability of progression to HCC. The sensitiv-
ity analysis examined the impact on the cost per QALY
of assuming that, antiviral therapy reduced the probabil-
ity of progression to HCC from cirrhosis even in the ab-
sence of SVR. In the sensitivity analysis, the probability of
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progression to HCC was reduced from 1.4 percent to 1 per-
cent, and the ICER for cirrhotic patients with genotype 1
aged 50 fell from £63,931 to £22,694. A threshold analy-
sis examined what reduction in the probability of HCC for
cirrhotic cases aged 50 with genotype 1, would be required
for treatment to become cost-effective. The results showed
that antiviral therapy was only cost-effective (ICER of less
than £20,000 ($40,000 or €29,200) for this subgroup, if the
probability of HCC for those cases not having a SVR was
0.9 percent or less, a reduction from baseline of at least one
third.
DISCUSSION
Previous cost-effectiveness studies of antiviral therapy for
chronic hepatitis C have found that antiviral therapy is gen-
erally cost-effective. However, these studies relied on SVR
rates from multinational RCTs that may not reflect those
achievable in routine clinical practice (27;28). Our study ex-
tends this previous literature and finds that based on SVR
rates reported in an observational setting, pegylated inter-
feron and ribavirin is cost-effective in routine practice for
patients with chronic hepatitis C. The study highlights that
the intervention is generally cost-effective for the subgroups
considered, although for the relatively small sample of older
patients with cirrhosis and genotype 1, the intervention was
less cost-effective.
An important reason why this study finds that pegylated
interferon and ribavirin is generally cost-effective in routine
clinical practice is that the SVR rates are almost as high as
in multinational RCTs (12;14;38). In this study, although the
mean durations of antiviral therapy exceeded those recom-
mended by NICE (12;17), they were similar to those ob-
served in the multinational RCTs. As newer shorter antiviral
treatment regimens are introduced, it can be anticipated that
antiviral treatment will become even more cost-effective. The
conclusion that the intervention is cost-effective in this set-
ting is also based on relevant estimates of disease progression
and cost. Previous studies used transition probabilities esti-
mated from patients attending tertiary referral centers, where
disease progression is faster than for more general popula-
tions (11).
Making comparisons of the cost-effectiveness of antivi-
ral therapy for chronic hepatitis C across different patient
groups was problematic before this study as estimates had to
be compared across studies which adopted different methods
(35). A clear advantage of this study is that the same data
sources and model are used to compare the cost-effectiveness
of antiviral therapy for different patient subgroups. This al-
lows the reasons for any differences in cost-effectiveness
across patient groups to be identified within this study.
While this study has emphasized the importance of
adopting a consistent methodology to subgroup analysis,
and using a data source that allows all parameters to vary
by subgroup, certain limitations should be noted. The results
suggesting that pegylated interferon and ribavirin is less cost-
effective for older patients with cirrhosis and genotype 1 were
driven by the low SVR (6 percent) predicted for this group.
It should be noted though, that the SVR rates for older, geno-
type 1 cases with cirrhosis were based on a small sample
size (n = 13), and so high levels of sampling variation sur-
round the central estimates. This study uses recommended
methods for incorporating this uncertainty through the use
of cost-effectiveness acceptability curves (CEACs). CEACs
summarize all the sampling uncertainty in the input param-
eters, by reporting the probability that the intervention is
cost-effective at different levels of willingness to pay for a
QALY gained. The results showed that the probability that
the intervention was cost-effective for patients with cirrhosis
did not exceed 0.5 at realistic levels of the ceiling ratio (19),
that is, the intervention was unlikely to be cost-effective. Pre-
vious studies have also found relatively low SVRs for older
patients with cirrhosis, and so the finding that antiviral ther-
apy is unlikely to be cost-effective for this group may well
apply more generally (32). However, an important area for
further research is to perform further CEA for antiviral treat-
ment compared with no treatment for larger samples of older
patients with genotype 1 and cirrhosis.
The cost-effectiveness estimates are based on the as-
sumption that disease progression is halted for those cases
having an SVR, and those patients who do not have an SVR
are assumed to face the same probabilities of progression as
untreated cases. A hypothesis in the literature is that even in
the absence of an SVR, antiviral treatment for patients with
cirrhosis may reduce the probability of progression to HCC
(22). The threshold analysis suggests that, unless the proba-
bility of progression from cirrhosis to HCC is reduced by one
third, the intervention is not cost-effective for this subgroup.
There is no clear evidence in the literature that antiviral ther-
apy for patients with cirrhosis can achieve this reduction in
progression to HCC (6;18). Like previous CEA models of
interventions for hepatitis C (13;27;28), we assume that, fol-
lowing an SVR, patients do not become reinfected with HCV.
Models in this area could be extended to allow for reinfec-
tion, but the available evidence suggests that reinfection rates
even among former IVDUs are low (9). Hence, it would be
highly unlikely that allowing for reinfection would make a
substantive difference to the finding that antiviral therapy is a
relatively cost-effective intervention for patients with chronic
hepatitis C.
CONCLUSIONS
In conclusion, this study finds that a combination of pegy-
lated interferon and ribavirin versus no antiviral treatment is
generally cost-effective when provided in a routine clinical
practice setting. The extensive subgroup analyses show that
antiviral treatment is cost saving for patients with genotype
non-1, and has low costs per QALY for most patient groups
with genotype 1. The study suggests that antiviral therapy
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is less cost-effective for older patients with genotype 1 and
cirrhosis.
POLICY IMPLICATIONS
This study provides policy makers with evidence that antivi-
ral therapy is generally cost-effective for chronic hepatitis C
using observational data that reflect the way patients are man-
aged in routine clinical practice. It therefore complements the
evidence available from RCT-based analyses. Policy makers
have to decide whether to restrict the availability of interven-
tions to particular subgroups, but this is often problematic as
it requires using cost-effectiveness evidence from studies that
adopt different methods. As this CEA is based on an observa-
tional data set that includes a broad range of patient groups
it can report cost-effectiveness according to subgroups of
interest to the policy maker. The CEA reports that, while
the intervention is cost-effective across most subgroups, for
one particular subgroup (older patients with genotype 1 and
cirrhosis) the intervention was less cost-effective. However,
the estimates for this subgroup were based on small samples
of patients, and further CEA focusing on this subgroup are
justified.
This approach is likely to be of interest to interna-
tional decision makers, and provides a complement to cost-
effectiveness analyses that have relied on multinational RCT
data. This approach could be extended to include groups such
as patients co-infected with HIV, excluded from the current
study. This study illustrates the value from using observa-
tional data sets in cost-effectiveness analysis and provides a
framework that subsequent economic evaluations could fol-
low.
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APPENDIX
Logistic regression analysis was used to calculate the probability
p of experiencing a sustained viral response (SVR), conditional on
the covariates x = (x1, x2, . . , xk)′ of interest. Whereas the logistic
model is expressed, in terms of the odds of experiencing the event
of interest:
p(x)
1 − p(x) = e
a + β1x1 + β2x2 + · · ·βkxK
the CEA required the predicted probability of SVR conditional on
the patient’s characteristics (e.g., age at treatment, disease stage,
and so on).
pˆ(x) = e
αˆ+ ˆβ1x1+ ˆβ2x2+···+ ˆβkxk
1 + eαˆ+ ˆβ1x1+ ˆβ2x2+···+ ˆβkxk
The coefficients required (αˆ and ˆβi) for calculating the
predicted probability of an SVR conditional on the pa-
tient’s characteristics were therefore estimated from the logistic
regression model : logit(p(X)) = a +
6∑
i=1
βixi +
11∑
i=7
βixi−6x6
where the patient characteristics (x1) are defined as:
x1 =
{
1 Male
0 Female
x2 =
{
1 Moderate disease stage
0 Otherwise
x3 =
{
1 Cirrhosis
0 Otherwise
x4 =
{
1 Biopsy score missing
0 Otherwise
x5 = Age at commencement of treatment (yrs)
x6 =
{
1 Genotype 1
0 Genotype Non − 1
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The predicted probabilities pˆ(x) are thus calculated as:
pˆ(x) = e
αˆ+
6∑
i=1
ˆβixi+
11∑
i=7
ˆβixi−6x6
1 + eαˆ+
6∑
i=1
ˆβixi+
11∑
i=7
ˆβixi−6x6
Using the above equation, the predicted probability of a SVR was
calculated for the individual or subgroup of interest by replacing
each xi with the relevant patient characteristics. These patient char-
acteristics were then combined with the estimated coefficients from
the multivariate logistic regression model:
αˆ = 2.14, ˆβ1 = −0.11, ˆβ2 = −0.69, ˆβ3 = −1.94,
ˆβ4 = −0.97, ˆβ5 = −0.013, ˆβ6 = −0.88
ˆβ7 = −0.60, ˆβ8 = −0.12, ˆβ9 = −0.39, ˆβ10 = 0.11, ˆβ11 = −0.056,
to give the predicted probability of a SVR for each sub group.
For example, the predicted probability of an SVR for a female
aged 40 with cirrhosis and genotype non-1(x1 = 0, x2 = 0, x3 =
1, x4 = 0, x5 = 40, x6 = 0) is
pˆ(x) = e
αˆ+ ˆβ3+40 ˆβ5
1 + eαˆ+ ˆβ3+40 ˆβ5 = 0.42
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